Clinical Trial Update: Study to Evaluate the Efficacy and Safety of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) in Japanese Adults With Subgenotype 1b Chronic Hepatitis C Virus (HCV) Infection [Phase 3]

View source ↗

Summary

This Phase 3 trial evaluated the efficacy and safety of the paritaprevir/ritonavir/ombitasvir regimen (ABT-450/r/ABT-267, Technivie) in Japanese adults with hep…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Ombitasvir (ombitasvir)
• Paritaprevir (paritaprevir)
• Ritonavir (Ritonavir)
• Technivie (Ombitasvir/paritaprevir/ritonavir)

Snippet

Sponsor: AbbVie | Conditions: Chronic Hepatitis C Infection | Phase 3 | Status: COMPLETED | Results posted: 2015-11-26